Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-11-20 00:00:00 ET · period of report 2025-11-18 · accession 0001213900-25-113114 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | 2025-11-18 | STLN | Ling Gabriel | Dir | J - Other | — | +141.1K | 250.2K | +129% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-18 | J | A | 141,149 | — | 250,206 | D | — | — | (F1) Consists of shares of common stock of the Issuer received by the reporting person through an in-kind distribution by M33 Growth I, L.P. to its limited partners and on a pro rata basis in accordance with their pecuniary interests therein in reliance on Rules 16a-9 and 16a-13 under the Securities Exchange Act of 1934, as amended. |